Versanis is dedicated to developing transformative treatments for obesity and cardiometabolic diseases by combining deep understanding of activin biology with Lilly's expertise in incretin biology
Versanis is dedicated to developing transformative treatments for obesity and cardiometabolic diseases by combining deep understanding of activin biology with Lilly's expertise in incretin biology. Their approach targets activin type II receptors to regulate fat and muscle metabolism, aiming to improve body composition and metabolic health in people living with obesity.